T-Cell Redirection in Oncology: Advancing Roles of Bispecific T-Cell Engagers and CAR T

The field of oncology has experienced a significant wave of innovation in next generation of T-cell directed approaches, including both chimeric antigen receptor T-cell therapies (CAR T) and bispecific antibody T-cell engagers (bispecific TCEs). It is critical for biotech and pharma companies to carefully evaluate their approach to innovation, and the corresponding tradeoffs that exist, as part of investing in either modality.

 

Download White Paper: T-Cell Redirection in Oncology: Advancing Roles of Bispecific T-Cell Engagers and CAR T